Literature DB >> 30998893

The Evolution of Phase-Separated TDP-43 in Stress.

Benjamin Wolozin1.   

Abstract

In this issue of Neuron, Gasset-Rosa et al. (2019) and Mann et al. (2019) demonstrate that cytoplasmic inclusions containing aggregated phosphorylated TDP-43 can evolve through three pathways: direct aggregation or phase-separated intermediates involving ejection from stress granules or seeding with exogenous fibrils. Interestingly, seeding with exogenous fibrils also induces cytoplasmic aggregates of nuclear pore proteins.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30998893      PMCID： PMC6816464          DOI： 10.1016/j.neuron.2019.03.041

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  10 in total

1.  Stress Granule Assembly Disrupts Nucleocytoplasmic Transport.

Authors:  Ke Zhang; J Gavin Daigle; Kathleen M Cunningham; Alyssa N Coyne; Kai Ruan; Jonathan C Grima; Kelly E Bowen; Harsh Wadhwa; Peiguo Yang; Frank Rigo; J Paul Taylor; Aaron D Gitler; Jeffrey D Rothstein; Thomas E Lloyd
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

2.  Spatiotemporal Control of Intracellular Phase Transitions Using Light-Activated optoDroplets.

Authors:  Yongdae Shin; Joel Berry; Nicole Pannucci; Mikko P Haataja; Jared E Toettcher; Clifford P Brangwynne
Journal:  Cell       Date:  2016-12-29       Impact factor: 41.582

3.  Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death.

Authors:  Fatima Gasset-Rosa; Shan Lu; Haiyang Yu; Cong Chen; Ze'ev Melamed; Lin Guo; James Shorter; Sandrine Da Cruz; Don W Cleveland
Journal:  Neuron       Date:  2019-03-07       Impact factor: 17.173

4.  RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.

Authors:  Jacob R Mann; Amanda M Gleixner; Jocelyn C Mauna; Edward Gomes; Michael R DeChellis-Marks; Patrick G Needham; Katie E Copley; Bryan Hurtle; Bede Portz; Noah J Pyles; Lin Guo; Christopher B Calder; Zachary P Wills; Udai B Pandey; Julia K Kofler; Jeffrey L Brodsky; Amantha Thathiah; James Shorter; Christopher J Donnelly
Journal:  Neuron       Date:  2019-02-27       Impact factor: 17.173

5.  Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p.

Authors:  Heather Stewart; Nicola J Rutherford; Hannah Briemberg; Charles Krieger; Neil Cashman; Marife Fabros; Matt Baker; Alice Fok; Mariely DeJesus-Hernandez; Andrew Eisen; Rosa Rademakers; Ian R A Mackenzie
Journal:  Acta Neuropathol       Date:  2012-01-07       Impact factor: 17.088

6.  The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.

Authors:  Ke Zhang; Christopher J Donnelly; Thomas E Lloyd; Jeffrey D Rothstein; Aaron R Haeusler; Jonathan C Grima; James B Machamer; Peter Steinwald; Elizabeth L Daley; Sean J Miller; Kathleen M Cunningham; Svetlana Vidensky; Saksham Gupta; Michael A Thomas; Ingie Hong; Shu-Ling Chiu; Richard L Huganir; Lyle W Ostrow; Michael J Matunis; Jiou Wang; Rita Sattler
Journal:  Nature       Date:  2015-08-26       Impact factor: 49.962

7.  Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization.

Authors:  Leeanne McGurk; Edward Gomes; Lin Guo; Jelena Mojsilovic-Petrovic; Van Tran; Robert G Kalb; James Shorter; Nancy M Bonini
Journal:  Mol Cell       Date:  2018-08-09       Impact factor: 17.970

8.  Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation.

Authors:  Tariq Afroz; Eva-Maria Hock; Patrick Ernst; Chiara Foglieni; Melanie Jambeau; Larissa A B Gilhespy; Florent Laferriere; Zuzanna Maniecka; Andreas Plückthun; Peer Mittl; Paolo Paganetti; Frédéric H T Allain; Magdalini Polymenidou
Journal:  Nat Commun       Date:  2017-06-29       Impact factor: 14.919

9.  TIA1 regulates the generation and response to toxic tau oligomers.

Authors:  Lulu Jiang; Peter E A Ash; Brandon F Maziuk; Heather I Ballance; Samantha Boudeau; Ali Al Abdullatif; Marcello Orlando; Leonard Petrucelli; Tsuneya Ikezu; Benjamin Wolozin
Journal:  Acta Neuropathol       Date:  2018-11-21       Impact factor: 17.088

10.  Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.

Authors:  Lindsay A Becker; Brenda Huang; Gregor Bieri; Rosanna Ma; David A Knowles; Paymaan Jafar-Nejad; James Messing; Hong Joo Kim; Armand Soriano; Georg Auburger; Stefan M Pulst; J Paul Taylor; Frank Rigo; Aaron D Gitler
Journal:  Nature       Date:  2017-04-12       Impact factor: 69.504
  10 in total
  5 in total

1.  Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules.

Authors:  Friederike Hans; Hanna Glasebach; Philipp J Kahle
Journal:  J Biol Chem       Date:  2019-11-28       Impact factor: 5.157

Review 2.  The basis of clinicopathological heterogeneity in TDP-43 proteinopathy.

Authors:  Ito Kawakami; Tetsuaki Arai; Masato Hasegawa
Journal:  Acta Neuropathol       Date:  2019-09-26       Impact factor: 17.088

Review 3.  Protein Aggregation in the Pathogenesis of Ischemic Stroke.

Authors:  Shusheng Wu; Longfei Du
Journal:  Cell Mol Neurobiol       Date:  2020-06-11       Impact factor: 5.046

4.  A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fibrillation in mice.

Authors:  Kensuke Ihara; Tetsuo Sasano; Yuichi Hiraoka; Marina Togo-Ohno; Yurie Soejima; Motoji Sawabe; Megumi Tsuchiya; Hidesato Ogawa; Tetsushi Furukawa; Hidehito Kuroyanagi
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

5.  Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice.

Authors:  Chunxing Yang; Tao Qiao; Jia Yu; Hongyan Wang; Yansu Guo; Johnny Salameh; Jake Metterville; Sepideh Parsi; Issa Yusuf; Robert H Brown; Huaibin Cai; Zuoshang Xu
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.